A foundational principle of American public health—identifying threats, deploying science-based solutions, and mobilizing public and political will—is eroding. Where policy was once forged through evidence, it is now frequently shaped by partisan calculation, exposing the nation to preventable crises. This represents a stark departure from the Progressive Era, when reformers, scientists, and government officials collaborated to bring scientific advances directly to protect public welfare.
The Straus Model: Evidence, Advocacy, Mandate
A pivotal case is the campaign led by philanthropist Nathan Straus to make milk safe. In the late 19th century, raw milk was a lethal vector for tuberculosis and cholera, contributing to infant mortality rates as high as 25% in cities like New York. Straus, a co-owner of Macy's driven by both religious conviction and personal tragedy—having lost a young daughter to suspected contaminated milk—decided to act.
Guided by pediatrician Abraham Jacobi, Straus launched a large-scale demonstration in 1893. He established 17 milk depots across Manhattan and the world's largest pasteurization plant, selling at cost and donating to the indigent. While directly serving only about 2,500 families daily, the initiative's power lay in rigorous documentation: it proved dramatic reductions in infant sickness and death.
From Pilot Program to Policy Victory
This data became the engine for change. Straus and a coalition of mothers' groups and medical researchers used it to pressure New York City officials, ultimately securing a municipal pasteurization mandate. The effort expanded nationally and internationally, facing fierce dairy industry opposition and navigating mixed medical and political reactions. By 1914, six of America's seven largest cities had enacted similar mandates, a testament to a model of change rooted in demonstrable results and sustained advocacy.
Today, that model feels distant. Federal health agencies are retreating from evidence-based positions on vaccines, delaying reviews, and scaling back investments in disease monitoring and epidemic preparedness. The growing chasm between scientific capability and political will to apply it represents a direct reversal of the Straus-era ethos.
This regression occurs amid a political climate where public health is increasingly contested. As seen in recent public opinion on foreign engagements, deep partisan divides now shape perceptions of risk and policy response, a dynamic that spills over into domestic health debates. The current approach to drug pricing, such as the bipartisan push for an insulin cost cap, shows that evidence-based policy is still possible but often emerges as an exception against a backdrop of polarization.
The Straus legacy demonstrates that science, when coupled with organized public demand, can compel accountability and drive systemic reform. His work created a template: identify a solvable problem, prove the solution works, and mobilize unrelenting pressure on policymakers. In an era where political advantage frequently overrides empirical data, this historical example serves as both a rebuke and a roadmap. The path forward requires reclaiming the conviction that public health policy must be anchored in evidence, not electoral strategy.
